TITLE: EFFECTIVE DATE: Sander Sepp, Healthcare Support Services Manager. Appendix 1 Healthcare Support Services process flow
|
|
- Suzan Ball
- 6 years ago
- Views:
Transcription
1 GlaxoSmithKline TITLE: Healthcare Support Services in GSK Estonia GSK ESTONIA STANDARD OPERATING PROCEDURE NUMBER: SOP/GSKEst/AD/048 EFFECTIVE VERSION: 01 DATE: SOP AUTHOR: Sander Sepp, Healthcare Support Services Manager Appendice(s): Appendix 1 Healthcare Support Services process flow Revised: Monika Isak, Quality Lead Supercedes: n/a Approval: Toomas Pruunsild, Medical Director Authorisation: Dan Millard, General Manager Page 1 of 6
2 History Date Version Short description Initial version Table of Contents 1. Purpose 2. Scope 3. Roles and Responsibilities 4. Definitions 5. Alignment 6. Procedure 7. References Appendix 1 Healthcare Support Services process flow Page 2 of 6
3 1. Purpose The purpose of this procedure is to define the approval process and governance structure for GlaxoSmithKline Eesti OÜ (hereinafter GSK Estonia) Healthcare Support Services. A Healthcare Support Service (HCSS) is any service which GSK provides, directly or indirectly, to Healthcare Organisations and/or patients and that has a defined purpose to achieve better health outcomes for patients, encance patient care or benefit healthcare. 2. Scope This Standard Operating Procedure (SOP) applies to all staff of GlaxoSmithKline Estonia who are involved in the set-up and management of HCSS. This SOP also applies to third parties where they perform all or part of a HCSS. 3. Roles and Responsibilities 3.1 The Business Owner of the HCSS is responsible for consulting local legal partner and/or GSK Legal prior to initiating new type of HCSS must inform NSC about all HCSS s in obtains approval for HCSS s from Management Team ensures final approval is obtained from the Medical Director via Zinc takes on the responsibility for all Initiator actions as per the ChimAERa process (SOP-GSKF- 400) provides HCSS status updates at least quarterly at Medical Governance Committee meetings and presents final report within a month after end of HCSS maintains proper documentation throughout the lifecycle of any HCSS and enures record retention in accordance with SOP/GSKEst/MD/ The Medical Director is responsible for reviewing and approving all HCSS s via Zinc, including all related materials. 3.3 The NSC is responsible for ensuring that adequate measures are taken for Adverse Event reporting training for recipients and 3rd party service providers of the HCSS routing and reconciliation of Adverse Event reports collected as part of the HCSS ensuring that any adverse event reports generated by the HCSS are tracked and maintained for efficient reporting in accordance with regulatory requests and in compliance with POL-GSK-400 and SOP/GSKEst/AD/ The Management team is responsible for endorsing all HCSS proposals before final approval is given by the Medical Director. 3.6 The Medical Governance Committee is responsible for the ongoing governance of all active HCSS s including making decisions on who is eligible to receive the service. This ongoing review and any decisions is recorded in the Medical Governance Committee minutes stored electronically in P:\Medical\MEDICAL AFFAIRS\Medical Affairs iganädalane koosolek. 3.7 Sales representatives may introduce, but must not provide, deliver or demonstrate healthcare support services. 4. Definitions Business HCSS Manager or any other member of GSK Estonia Medical Affairs team Owner ChimAERa GSK corporate program for ensuring compliance with SOP-SGKF-400 Page 3 of 6
4 HCSS NSC SOP Healthcare Support Service Any service which GSK provides, directly or indirectly, to Healthcare Organisations and/or patients and that has a defined purpose to achieve better health outcomes for patients, encance patient care or benefit healthcare. It can bear company branding but must not bear the name of any medicine or product. The involvement of GSK in the provision of HCSS must be made clear to all recipients of the service. HCSS must not be designed to promote any medicines and must be kept clearly seperate from the activities for the promotion of medicines. Patient confidentiality must be maintained at all times. The provision of HCSS must not constitute an inducement to recommend, prescribe, purchase, supply, selle or administer specific medicines or for the purpose of sales representative or other GSK representative gaining access to a medical facility. HCSS must not be provided to individual Healthcare practitioners for their personal benefit or their own financial advantage. HCSSs must not be provided to underwrite a commercial business or generate income to for a Healthcare practitioner, practice, administrative staff or other Helthcare Organisation. GSK must not engage, nor provide funding for the engagement of Healthcare practitioners to perform an activity that includes recommending or prescribing a particular medicine Named Safety Contact Standard Operating Procedure 5. Alignment This procedure is written in accordance with the requirements of the following external legislation and internal GSK Global Policies: Estonian Medicinal Products Act Chapter 4. Advertising Medicinal Products and Inducement Designed to Promote Sales and Prescription EFPIA Code on Disclosure of Transfers of Value From Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations STD-GSK-401 GSK Code of Practice for Promotion and Customer Interactions POL-GSK-400 Management of Human Safety Information for GSK Products 6. Procedure See Appendix 1 for the summary process flow. 6.1 A team (if applicable) is created and a Business Owner assigned for the HCSS. For the purposes of this SOP, the Business Owner takes on the role of 'Initiator' as per SOP-GSKF-400. Business Owners for HCSSs are limited to HCSS Manager and other members of Medical Affairs team. 6.2 If new type of HCSS is being developed local legal partner and/or GSK Legal need to be consulted to ensure compliance with local laws and GSK requirements. 6.3 The HCSS Business Owner develops the HCSS and brings a proposal to the GSK Estonia Management team. Management team can either approve the HCSS, approve it conditionally after requested amendments are made, ask to amend and resubmit or reject the HCSS proposal. 6.4 Business owner submits the HCSS to Medical Director for final approval via Zinc. 6.5 Prior to HCSS initiation NSC has to be informed by . New HCSSs are introduced to Medical Governance Committee at their regular meetings. Making HCSS governance decisions (i.e. who is eligible to receive the service) is responsibility of the Medical Governance Committee. Business Owner provides at least quarterly updates to the Medical Governance Committee and a final report Page 4 of 6
5 within a month after the closure of HCSS to Medical Governance Committee and if requested to the Management team. 6.6 Throughout the lifetime of the HCSS Business Owner is responsible for maintaining proper documentation and ensuring record retention in line with project ChimAERa (SOP-SGKF-400 'Project Execution' and 'Reconcile, Record & Store') and SOP/GSKEst/MD/ References SOP/GSKEst/MD/022 Archiving of Clinical Trial Documentation and Other Medical Department Records within GSK Estonia Medical Department SOP-SGKF-400 Procedure for identification and tracking of Patient Support Programmes (PSP), Market Research (MR) and Interactive Digital Media (IDM) activities that may generate human safety information for GSK Products SOP/GSKEst/AD/029 Standard Operating Company Procedure for Pharmacovigilance, Materiovigilance, cosmetovigilance, nutrivigilance and Human Safety Related Activities Page 5 of 6
6 Appendix 1 - Healthcare Support Services process flow Page 6 of 6
ACTIONS/PSOP/001 Version 1.0 Page 2 of 6
1. The purpose of the Pharmacy Site File To enable the designated trust pharmacy to fulfil its role and exercise appropriate control over all aspects of study medication handling, an accurately maintained
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Delegated Responsibilities in Research Projects SOP Number: 11 Version Number: 2.0 Supercedes: 1.0 Effective date: August
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Maintaining Training Records SOP Number: 20 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date:
More informationGood Practice Principles:
NHMC National Homecare Medicines Committee Good Practice Principles: Provision of Manufacturer Funded Homecare Medicines Services National Homecare Medicines Committee February 2018 Version 1 Definitions
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationGuidance on Standard Operating Procedures for the Safer Management of Controlled Drugs in Registered Facilities. July 2011
Guidance on Standard Operating Procedures for the Safer Management of Controlled Drugs in Registered Facilities July 2011 Introduction: This guidance sets out strengthened governance arrangements required
More informationSTANDARD OPERATING PROCEDURE SOP 325
STANDARD OPERATING PROCEDURE SOP 325 STUDY START UP ACTIVITIES FOR CLINICAL RESEARCH TRIALS Version 1.4 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 7 Review date April 2019 Author
More informationREGULATION IN THE TELEHEALTHCARE SECTOR IN RUSSIA: LEGAL DEVELOPMENTS
REGULATION IN THE TELEHEALTHCARE SECTOR IN RUSSIA: LEGAL DEVELOPMENTS www.gratanet.com The Federal Law No. 242-FZ dated 29 July 2017 amended certain legislative acts of the Russian Federation on the use
More informationM Rickard, Research Governance and GCP Manager Elizabeth Clough, R&D Governance Operations Manager Rachel Fay, Research Governance and GCP Manager
Standard Operating Procedures (SOP) for: Reporting Incidents Related to Research SOP Number: 027 Version Number: 4.0 Effective Date: 03 rd September 2015 Review Date: 02 nd September 2018 Author: Reviewer:
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationQuality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D
Quality Assurance in Clinical Research at RM/ICR GCP Compliance Team, Clinical R&D Slide 1 of 13 What is Quality Assurance? The maintenance of a desired level of quality in a service or product, especially
More informationProposed amendments to the Marihuana for Medical Purposes Regulations
Proposed amendments to the Marihuana for Medical Purposes Regulations Submission in response to the Canada Gazette publication on the proposed amendments to the Marihuana for Medical Purposes Regulations
More informationGuidelines on the Keeping of Records in Respect of Medicinal Products when Conducting a Retail Pharmacy Business
Guidelines on the Keeping of Records in Respect of Medicinal Products when Conducting a Retail Pharmacy Business to facilitate compliance with Regulation 12 of the Regulation of Retail Pharmacy Businesses
More informationASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics. March 2018
ASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics March 2018 Introduction Improving patient access to affordable medicines is a core value of companies that develop and manufacture generic and
More informationGuidance notes for patient safety and pharmacovigilance in patient support programmes
Guidance notes for patient safety and pharmacovigilance in patient support programmes Authors: The ABPI Pharmacovigilance Expert Network Version: 2.14 Date: March 2018 Acknowledgements: We thank the many
More information1. INTRODUCTION 2. SCOPE 3. PROCESS
1. INTRODUCTION This document describes the procedure for establishing and maintaining records for staff training and complies with the principles of good clinical practice (GCP) for clinical trials of
More informationRecords Management Code of Practice for Health and Social Care 2016
Records Management Code of Practice for Health and Social Care 2016 Sarah Graham, NHS England, 28 th April 2017 Introduction Main focus of the presentation - key messages within the Information Governance
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationResearch Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004
Title: Outcome Statement: Research Auditing and Monitoring Procedures Researchers in the Trust and research partners will be informed about the requirements and procedures involved in research audit and
More informationApplication for Membership of The Association of the British Pharmaceutical Industry
To be returned to: The Secretary 7 th Floor, Southside, 105 Victoria Street, London SW1E 6QT +44 (0)20 7930 3477 membership@abpi.org.uk Application for Membership of The Association of the British Pharmaceutical
More informationGuidance on the Delivery of Medicines Dispensed on Foot of a Prescription from a Retail Pharmacy Business
Guidance on the Delivery of Medicines Dispensed on Foot of a Prescription from a Retail Pharmacy Business Pharmaceutical Society of Ireland Version 1 July 2014 Contents 1. Introduction 2 2. Guidance 3
More informationEffective Date: 11/09 Policy Chronicle:
Title: Investigational Drug Service Functions Policy Type: Clinical Operations Replaces (supersedes): Title: N/A Policy Chronicle: Date Original Version of Policy was Effective: 09/06 Reviewer Signature:
More informationMEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC
MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Memorandum of understanding between MHRA, COREC and GTAC 1. Purpose and scope 1.1 Regulation 27A of the Medicines for Human Use (Clinical Trials)
More informationDocument Title: Study Data SOP (CRFs and Source Data)
Document Title: Study Data SOP (CRFs and Source Data) Document Number: SOP047 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationStandard Operating Procedure Research Governance
Research and Enterprise Standard Operating Procedure Research Governance Title: Research Governance Audit SOP Reference Number: QUB-ADRE-08 Date prepared 7 August 008 Version Number: Final v -6.0 Revision
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Sponsorship SOP-RES-001 Version Number 3 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s) Teresa
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationAll areas of the Trust All Trust staff All Patients Deputy Chief Nurse & Chief Pharmacist Final
Trust Policy and Procedure Document Ref. No: PP(15)233 Non-Medical Prescribing Policy For use in: For use by: For use for: Document owner: Status: All areas of the Trust All Trust staff All Patients Deputy
More informationConditions and procedure for applying for, awarding and amending the amount of institutional research funding. Chapter 1 General Provisions
Conditions and procedure for applying for, awarding and amending the amount of institutional research funding Adopted 27 December 2011 No. 73 The regulation is established on the basis of Subsection 15
More informationDocument Title: Investigator Site File. Document Number: 019
Document Title: Investigator Site File Document Number: 019 Version: 1.1 Ratified by: R&D Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationStandard Operating Procedure (SOP)
Standard Operating Procedure MANAGEMENT OF BREACHES IN RESEARCH SETTING AUDIENCE ISSUE Trustwide for research sponsored by UHBristol All research staff involved in UH Bristol sponsored research This SOP
More informationMedicines Reconciliation: Standard Operating Procedure
Clinical Medicines Reconciliation: Standard Operating Procedure Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Principles of Data Collection and Storage SOP Number: 8 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationCOMMUNITY PHARMACY MINOR AILMENTS SERVICE
COMMUNITY PHARMACY MINOR AILMENTS SERVICE SUPPORTING SELF-CARE OCTOBER 2010 CONTENTS Index Page No 1 Introduction 3 2 Service Specification 4 3 Consultation Procedure 7 4 Re-ordering Documentation 10 Appendices
More informationQualification details
Outcome Statement Qualification details Title New Zealand Certificate in Pharmacy (Specialist Technician) (Level 6) Version 1 Qualification type Certificate Level 6 Credits 120 NZSCED 060501 Health > Pharmacy
More informationTRAINING REQUIREMENTS FOR RESEARCH STAFF, INCLUDING GOOD CLINICAL PRACTICE (GCP)
Reference Number: UHB 317 Version Number: 1 Date of Next Review: 7th July 2019 Previous Trust/LHB Reference Number: N/A TRAINING REQUIREMENTS FOR RESEARCH STAFF, INCLUDING GOOD CLINICAL PRACTICE (GCP)
More informationADMINISTRATION OF MEDICATED EYE DROPS PRIOR TO EYE EXAMINATION FOR NURSING STAFF IN THE OPHTHALMOLOGY DEPARTMENT
ADMINISTRATION OF MEDICATED EYE DROPS PRIOR TO EYE EXAMINATION FOR NURSING STAFF IN THE OPHTHALMOLOGY DEPARTMENT Version Number V2 Date of Issue April 2018 Reference Number Review Interval Approved By
More informationStandard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-06-003 Essential Documents: Setting Up a Trial Master File SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature:
More informationNHS Prescription Services CPAF Screening Questionnaire 2018/19
NHS Prescription Services CPAF Screening Questionnaire 08/9 Important Information about this Document This is a reference copy of the Community Pharmacy Assurance Framework Screening Questionnaire, the
More informationGuidelines for Industrial Postdoc In force as of 9 March 2015
Guidelines for Industrial Postdoc In force as of 9 March 2015 Contents 1. What is an Industrial Postdoc?... 1 2. General conditions... 3 3. Entry requirements... 4 4. Application... 5 5. Decision on applications...
More informationTerms & Conditions of Award
PART 1 1. INTRODUCTION 1 Terms & Conditions of Award 1.1. Part 1 of this Terms & Conditions of Award document sets out the standard terms and conditions for all British Academy awards. Additional terms
More informationPolicy for Access to MINDACT Biological Materials and Data
Policy for Access to MINDACT Biological Materials and Data Public Version 8 Contents 1. Introduction... 3 2. Glossary... 3 3. Governance and responsibilities... 5 4. General principles... 5 5. Review Procedures...
More informationUnderstanding the Pharmacy and Drug Act amendments and mail order pharmacy licensing
Understanding the Pharmacy and Drug Act amendments and mail order pharmacy licensing Background As reported in the Spring 2009 issue of acpnews, ACP and Alberta Health and Wellness developed a new policy
More informationGrünenthal Norway AS - Methodological Note
Grünenthal Norway AS - Methodological Note Guidelines for Implementing the EFPIA Disclosure (Transparency) Code for the Reporting Year 2016 Preamble As a member company of the European Federation of Pharmaceutical
More informationInformation shared between healthcare providers when a patient moves between sectors is often incomplete and not shared in timely enough fashion.
THE DISCHARGE MEDICINES REVIEW SERVICE Introduction During a stay in hospital a patient s medicines may be changed. Studies show that many patients may experience an error or problem with their medicines
More informationDocument Details. notification of entry onto webpage
Document Details Title Patient Group Direction (PGD) Administration of sodium chloride 0.9% injection by registered professionals Trust Ref No 1987-38096 Local Ref (optional) Main points the document As
More informationINDEPENDENT NON-MEDICAL PRESCRIBING (NMPs) POLICY. Suffolk GP Federation Board
INDEPENDENT NON-MEDICAL PRESCRIBING (NMPs) POLICY Version: 1.0 Policy owner: Ratified by: Clinical Governance Lead Chief Executive Date approved: 28 th November 2014 Approved by: Suffolk GP Federation
More informationAccreditation and Recognition of pharmacy assistant/dispenser and Medicines Counter assistant training programmes
Accreditation and Recognition of pharmacy assistant/dispenser and Medicines Counter assistant training programmes Contents 1. Introduction 3 Support staff training programmes Criteria for accreditation
More informationInvestigator Site File Standard Operating Procedure (SOP)
Investigator Site File Standard Operating Procedure (SOP) DOCUMENT CONTROL: Version: 1 Ratified by: Quality and Safety Sub Committee Date ratified: 30 January 2017 Name of originator/author: Research Nurse
More informationClinical. Prescribing Medicines SOP. Document Control Summary. Contents
Clinical Prescribing Medicines SOP Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date: Key
More informationList of Policies and Standard Operational Procedures (SOPs) for cell collection, processing and transplantation programmes
Format of SOPs (SOPs) for cell collection, processing and transplantation programmes There must be an SOP covering the procedure of preparing, implementing and revising all procedures and an SOP for document
More informationGuidance on the Supply by Pharmacists in Retail Pharmacy Businesses of Medicines to Patients in Residential Care Settings/Nursing Homes
Guidance on the Supply by Pharmacists in Retail Pharmacy Businesses of Medicines to Patients in Residential Care Settings/Nursing Homes Pharmaceutical Society of Ireland Version 4 March 2018 Updates made
More informationSERVICE LEVEL AGREEMENT: University of Arkansas for Medical Sciences OFFICE OF SPONSORED PROGRAMS ADMINISTRATIVE NETWORK (OSPAN)
SERVICE LEVEL AGREEMENT: University of Arkansas for Medical Sciences OFFICE OF SPONSORED PROGRAMS ADMINISTRATIVE NETWORK (OSPAN) Table of Contents Complete later Section I General Information and Objectives
More informationTrust Policy and Procedure Document Ref. No: PP (17) 283. Central Alerting System (CAS) Policy and Procedure. For use in: For use by: For use for:
Trust Policy and Procedure Document Ref. No: PP (17) 283 Central Alerting System (CAS) Policy and Procedure For use in: For use by: For use for: Document owner: Status: All areas of the Trust including
More informationMedicines Reconciliation Standard Operating Procedures
Creator Sam Carvell, Amber Wynne, Sue Coppack Version 1 Review Date Medicines Reconciliation Standard Operating Procedures Purpose of SOP This standard operating procedure (SOP) provides a framework for
More informationNCCP Guidance on the Retention and Disposal of Systemic Anti-Cancer Therapy (SACT) prescriptions and compounding worksheets.
NCCP Guidance on the Retention and Disposal of Systemic Anti-Cancer Therapy (SACT) prescriptions and compounding worksheets. Version Date Amendment Approved By 1 11/01/2017 Version 1 NCCP following consultation
More informationNHS Prescription Services CPAF Screening Questionnaire 2017/18
NHS Prescription Services CPAF Screening Questionnaire 207/8 Important Information about this Document This is a reference copy of the Community Pharmacy Assurance Framework Screening Questionnaire, the
More informationEvaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes
Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes 2 nd Adverse Event Reporting and Safety Strategies Summit December 8-9, 2015
More informationNAMIBIA MEDICINES REGULATORY COUNCIL MINISTRY OF HEALTH AND SOCIAL SERVICES
1 NAMIBIA MEDICINES REGULATORY COUNCIL MINISTRY OF HEALTH AND SOCIAL SERVICES FEES PAYABLE TO THE REGISTRAR (Regulation 47) 1. In respect of an application for registration of a Category A medicine - (a)
More informationStandards for Registered Pharmacies
Council meeting 13 September 2012 Public business Standards for Registered Pharmacies Purpose This paper seeks the Council s approval of the standards for registered pharmacies. The Council is asked to
More informationProfessional Practices Policy (P3)
Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN NOVARTIS GLOBAL POLICY 2 Contents 1 Introduction... 3 2 Principles... 4 3 Policy...
More informationSTANDARD OPERATING PROCEDURE SOP 345. Identifying Trial Patients on Hospital Admission
STANDARD OPERATING PROCEDURE SOP 345 Identifying Trial Patients on Hospital Admission Version 1.3 Version date 22/02/2018 Effective date 24/02/2018 Number of pages 6 Review date January 2020 Author Role
More informationUnique Identifier: Review Date: November Issue Status: Approved Version No: 1.4 Issue Date: November 2017
Policy Authors Name & Title: Dr Mark Jackson, Director of Research & Informatics Dr Raphael Perry, Medical Director Scope: Trust Wide Classification: Non Clinical Replaces: version 1.3 To be read in conjunction
More informationThis Agreement dated DD/MM/YYYY (the Effective Date ) is between
Clinical Trial Delegation of Sponsorship Responsibilities to Chief This Agreement dated DD/MM/YYYY (the Effective Date ) is between Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7
More informationMedicines Reconciliation Policy
Medicines Reconciliation Policy Lead executive Medical Director Authors details Senior Clinical Pharmacy Technician - 01244 39 7494 Document level: Trustwide (TW) Code: MP19 Issue number: 3 Type of document
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationDocument Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator
including Roles and Responsibilities for the Conduct of Research Studies and Clinical Trials including CTIMPs (Clinical Trials of Investigational Medicinal Products) Document Number: 006 Version: 1 Ratified
More informationCriteria / Observations
Observations Index It is the company s individual decision to sponsor / participate in the event. Companies belonging to the EFPIA membership should be mindful of the rules and provisions that apply when
More informationSTH Researcher. Recording of research information in patient case notes
STANDARD OPERATING PROCEDURE STH Researcher Recording of research information in patient case notes SOP History None SOP Number A108 Created Research Department (AL) SUPERSEDED Final 1.3 Version 3.5 Date
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Recording and Reporting Deviations, Violations, Potential Serious Breaches, Serious Breaches and Urgent Safety Measures
More informationSUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION
SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION GUIDANCE FOR PHARMACISTS ON SAFE SUPPLY TO PATIENTS (This
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 26 July 2012 EMA/118465/2012 3 4 Guideline on good pharmacovigilance practices (GVP) Module XV Safety communication 5 Draft finalised by the Agency in collaboration with Member States and submitted
More informationHealth Visitor and School Nurse Preceptorship Guidance. Version No 2
Livewell Southwest Health Visitor and School Nurse Preceptorship Guidance Version No 2 Notice to staff using a paper copy of this guidance The policies and procedures page of LSW intranet holds the most
More informationTexas Administrative Code
RULE 19.1501 Pharmacy Services A licensed-only facility must assist the resident in obtaining routine drugs and biologicals and make emergency drugs readily available, or obtain them under an agreement
More informationCancer Research UK Clinical Trials/Research Unit Glasgow. Quality System
Cancer Research UK Clinical Trials/Research Unit Glasgow Quality System BEATSON WEST OF SCOTLAND CANCER CENTRE POLICY ON THE AWARENESS AND TRAINING OF STAFF MANAGING PATIENTS WITHIN THE CONTEXT OF A CLINICAL
More informationHow GSK supports independent medical education
How GSK supports independent medical education GlaxoSmithKline s mission is to help people do more, feel better, live longer. As part of this mission we are embarking on a new initiative in how we support
More informationConsultation on developing our approach to regulating registered pharmacies
Consultation on developing our approach to regulating registered pharmacies May 2018 The text of this document (but not the logo and branding) may be reproduced free of charge in any format or medium,
More informationHigh Level Pharmaceutical Forum
High Level Pharmaceutical Forum 2005-2008 Final Conclusions and Recommendations of the High Level Pharmaceutical Forum On 2 nd October 2008, the High Level Pharmaceutical Forum agreed on the following
More informationReconciliation of Medicines on Admission to Hospital
Reconciliation of Medicines on Admission to Hospital Policy Title State previous title where relevant. State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For
More informationStrengthening Quality and Accountability for Patients Act, 2017 (Bill 160): What You Need to Know. Bill 160: Background
Strengthening Quality and Accountability for Patients Act, 2017 (Bill 160): What You Need to Know Christelle Gedeon, Associate Laurie Turner, Associate October 30, 2017 Bill 160: Background Omnibus legislation
More informationCCG Policy for Working with the Pharmaceutical Industry
CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry
More informationUncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES
Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company
More informationThe Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector
The Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector E thical interactions help ensure that medical decisions are made in the best interests of patients. For
More informationApplication Guide for the Aboriginal Participation Fund
Application Guide for the Aboriginal Participation Fund Overview of the Mineral Development Advisor Positions and Support Funding Streams What You Need to Know Before You Apply Before completing your application
More informationProcedure For Training In Use Of Human Tissue Obtained For Research Purposes
Reference Number: UHB 137 Version Number: 2 Date of Next Review: 11 TH Oct 2019 Previous Trust/LHB Reference Number: Procedure For Training In Use Introduction and Aim The Human Tissue Act 2004 (HT Act)
More informationQuality ID #46 (NQF 0097): Medication Reconciliation Post-Discharge National Quality Strategy Domain: Communication and Care Coordination
Quality ID #46 (NQF 0097): Medication Reconciliation Post-Discharge National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
More informationEFPIA Code of Practice on relationships between the pharmaceutical industry and patient organisations
EFPIA Code of Practice on relationships between the pharmaceutical industry and patient organisations Luc Hessel M.D. European Vaccine Manufacturers vm-vaccines.org www.evm-vaccines.org www.evm-vaccines.org
More informationGovernance %%.4- r2&% Queen s University Belfast. Standard Operating Procedure Research Governance. r2.aoc7. Research and Enterprise
Queen s University Belfast Research and Enterprise Standard Operating Procedure Research Governance Title: Delegation of Responsibilities SOP Reference QUB-ADRE-005 Date prepared 23 June 2008 Number: Version
More informationExternal Assessment Specifications Document
External Assessment Specifications Document Curriculum Code: 321301000 Qualification Title: Occupational Certificate: Pharmacy Technician NQF Level: 6 321301000 - Pharmacy Technician External Assessment
More informationDirect Patient ADR reporting system in Japan. Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Direct Patient ADR reporting system in Japan Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions expressed in the following PowerPoint
More informationCLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD)
CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD) DEFINITION A Patient Group Direction (PGD) is a specific written instruction for the supply and administration
More informationWORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0
WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0 1 Standard Operating Procedure St Helens CCG Working with The Pharmaceutical Industry Policy Version 1.0 Implementation Date May 2017 Review
More informationRegulation Directorate Key Performance Indicators
Council meeting 19 May 2010 Business paper public business Regulation Directorate Key Performance Indicators Purpose This paper provides information on the Royal Pharmaceutical Society s (RPSGB s) Regulation
More informationControlled Drugs Policy
Controlled Drugs Policy Controlled Drugs Policy Who Should Read This Policy Target Audience All Consultant/Senior Medical Staff All Junior Medical Staff All Non-Medical Prescribers All Pharmacy Staff All
More informationBest Practice Guidelines - BPG 9 Managing Medicines in Care Homes
Best Practice Guidelines - BPG 9 Managing Medicines in Care Homes Medicines in Care Homes 1 DOCUMENT STATUS: Approved DATE ISSUED: 10 th November 2015 DATE TO BE REVIEWED: 10 th November 2017 AMENDMENT
More informationJOB DESCRIPTION. 1 year fixed term. Division A Pharmacy. University Hospitals Birmingham. Advanced Clinical Pharmacist Trials.
JOB DESCRIPTION JOB TITLE: Pharmacy Technician Haematology Clinical Trials PAY BAND: Agenda for change - Band 5 TERMS AND CONDITIONS DEPARTMENT/DIVISION: BASED AT: REPORTS TO: PROFESSIONALLY RESPONSIBLE
More informationCorporate. Research Governance Policy. Document Control Summary
Corporate Research Governance Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date:
More informationAuthority to Prescribe Medications Policy
Department of Health and Human Services SYSTEM PURCHASING AND PERFORMANCE - MEDICATION STRATEGY AND REFORM Authority to Prescribe Medications Policy SDMS Id Number: Effective From: June 2014 Replaces Doc.
More informationNATO UNCLASSIFIED ARCHIVES COMMITTEE. Directive on the Public Disclosure of NATO Information
04 August 2014 DOCUMENT ARCHIVES COMMITTEE Directive on the Public Disclosure of NATO Information The Directive on the Public Disclosure of NATO Information was approved by the Archives Committee under
More informationSOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils
Title: Assessment of Study Feasibility Manual: RI MUHC Policies and Procedures Human Research SOPs Originating Dept/ Service: RI MUHC Division of Clinical Research SOP: New Revised Reviewed Effective Date:
More information